Identification of Nkx2–3 and TGFB1I1 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy

References

• Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005; 365:153 - 65; http://dx.doi.org/10.1016/S0140-6736(05)17706-X; PMID: 15639298
   PubMed Web of Science ®Google Scholar
• Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 2005; 104:2035 - 47; http://dx.doi.org/10.1002/cncr.21462; PMID: 16206296
   PubMed Web of Science ®Google Scholar
• Lorenz M, Staib-Sebler E, Hochmuth K, Heinrich S, Gog C, Vetter G, et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol 2000; 27:Suppl 10 112 - 9; PMID: 11049042
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23 - 30; http://dx.doi.org/10.1200/JCO.2004.09.046; PMID: 14665611
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23:9441 - 2; http://dx.doi.org/10.1200/JCO.2005.04.4792; PMID: 16361649
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011 - 27; http://dx.doi.org/10.1200/JCO.2005.06.081; PMID: 15585754
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3:24 - 40; http://dx.doi.org/10.1038/ncponc0403; PMID: 16407877
   PubMedGoogle Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013 - 9; http://dx.doi.org/10.1200/JCO.2007.14.9930; PMID: 18421054
   PubMed Web of Science ®Google Scholar
• Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356:1667 - 71; http://dx.doi.org/10.1016/S0140-6736(00)03167-6; PMID: 11089838
   PubMed Web of Science ®Google Scholar
• Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1:65 - 70; http://dx.doi.org/10.1038/sj.tpj.6500012; PMID: 11913730
   PubMedGoogle Scholar
• Gustavsson B, Kaiser C, Carlsson G, Wettergren Y, Odin E, Lindskog EB, et al. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int J Cancer 2009; 124:1220 - 6; http://dx.doi.org/10.1002/ijc.23852; PMID: 19051292
   PubMed Web of Science ®Google Scholar
• Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18:504 - 9; http://dx.doi.org/10.1093/annonc/mdl430; PMID: 17322540
   PubMed Web of Science ®Google Scholar
• Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63:1311 - 6; PMID: 12649192
   PubMed Web of Science ®Google Scholar
• Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. ERCC1 codon 118 C-T polymorphism associated with ERCC 1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. J. Cancer Sci 2008; 12:278 - 83
   Google Scholar
• Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003; 1:162 - 6; PMID: 16224397
   PubMedGoogle Scholar
• Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, et al. Association between polymorphisms of ERCC1 and XPD and survival in non small-cell lung cancer patients treated wide cisplatin combination chemothempy. Lung Cancer 2004; 1:311 - 6; http://dx.doi.org/10.1016/j.lungcan.2003.11.019
   Web of Science ®Google Scholar
• Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007; 56:281 - 8; http://dx.doi.org/10.1016/j.lungcan.2006.12.002; PMID: 17222938
   PubMed Web of Science ®Google Scholar
• Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005; 11:6212 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-04-2216; PMID: 16144923
   PubMed Web of Science ®Google Scholar
• Chen J, Xie F, Chen K, Wang D, Jiang H, Li J, et al. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Cancer Biol Ther 2009; 8:1424 - 30; http://dx.doi.org/10.4161/cbt.8.14.8889; PMID: 19458483
   PubMed Web of Science ®Google Scholar
• Suh KW, Kim JH, Kim Y, Kim YB, Lee C, Choi S. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?. Ann Surg Oncol 2006; 13:1379 - 85; http://dx.doi.org/10.1245/s10434-006-9112-y; PMID: 17009149
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94:936 - 42; http://dx.doi.org/10.1093/jnci/94.12.936; PMID: 12072547
   PubMed Web of Science ®Google Scholar
• Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26:2690 - 8; http://dx.doi.org/10.1200/JCO.2007.15.5580; PMID: 18509181
   PubMed Web of Science ®Google Scholar
• Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. Eur J Cancer 2009; 45:1935 - 49; http://dx.doi.org/10.1016/j.ejca.2009.04.023; PMID: 19473832
   PubMed Web of Science ®Google Scholar
• Hou L, Li Y, Jia YH, Wang B, Xin Y, Ling MY, et al. Molecular mechanism about lymphogenous metastasis of hepatocarcinoma cells in mice. World J Gastroenterol 2001; 7:532 - 6; PMID: 11819823
   PubMed Web of Science ®Google Scholar
• Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM. Expression Profiling using DNA microarrays. Nature Gene ties Supplement 1999; 21:10-14.
   Google Scholar
• Wen WH, Bernstein L, Lescallett J, Beazer-Barclay Y, Sullivan-Halley J, White M, et al. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 2000; 60:2716 - 22; PMID: 10825146
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205 - 16; http://dx.doi.org/10.1093/jnci/92.3.205; PMID: 10655437
   PubMed Web of Science ®Google Scholar
• Yu W, Lin Z, Pastor DM, Hegarty JP, Chen X, Kelly AA, et al. Genes regulated by Nkx2-3 in sporadic and inflammatory bowel disease-associated colorectal cancer cell lines. Dig Dis Sci 2010; 55:3171 - 80; http://dx.doi.org/10.1007/s10620-010-1138-0; PMID: 20165982
   PubMed Web of Science ®Google Scholar
• Wang X, Zbou C, Qiu G, Fan J, Tang H, Peng Z. Screening of new tumor suppressor genes in sporadic colorectal cancer patients. Hepatogastroenterology 2008; 55:2039 - 44; PMID: 19260473
   PubMed Web of Science ®Google Scholar
• Cai G, Huang H, Shapiro E, Zhou H, Yeh S, Melamed J, et al. Expression of androgen receptor associated protein 55 (ARA55) in the developing human fetal prostate. J Urol 2005; 173:2190 - 3; http://dx.doi.org/10.1097/01.ju.0000158119.34126.70; PMID: 15879885
   PubMed Web of Science ®Google Scholar
• Yund EE, Hill JA, Keller RS. Hic-5 is required for fetal gene expression and cytoskeletal organization of neonatal cardiac myocytes. J Mol Cell Cardiol 2009; 47:520 - 7; http://dx.doi.org/10.1016/j.yjmcc.2009.06.006; PMID: 19540241
   PubMed Web of Science ®Google Scholar
• Heitzer MD, DeFranco DB. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res 2006; 66:7326 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-05-2379; PMID: 16849583
   PubMed Web of Science ®Google Scholar
• Dabiri G, Tumbarello DA, Turner CE, Van de Water L. Hic-5 promotes the hypertrophic scar myofibroblast phenotype by regulating the TGF-beta1 autocrine loop. J Invest Dermatol 2008; 128:2518 - 25; http://dx.doi.org/10.1038/jid.2008.90; PMID: 18401422
   PubMed Web of Science ®Google Scholar
• Dabiri G, Tumbarello DA, Turner CE, Van de Water L. TGF-beta1 slows the growth of pathogenic myofibroblasts through a mechanism requiring the focal adhesion protein, Hic-5. J Invest Dermatol 2008; 128:280 - 91; PMID: 17671518
   PubMed Web of Science ®Google Scholar
• Wang H, Song K, Krebs TL, Yang J, Danielpour D. Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. Oncogene 2008; 27:6791 - 805; http://dx.doi.org/10.1038/onc.2008.291; PMID: 18762808
   PubMed Web of Science ®Google Scholar
• Stavit Drori1, Geoffrey D. Girnun, Liqiang Tou, Jeffrey D. Szwaya, Elisabetta Mueller, Xia Kia, et al. Hic-5 regulates an epithelial program mediated by PPARgamma. Genes Dev 2005; 19(3): 361-375.
   Google Scholar
• Osada M, Ohmori T, Yatomi Y, Satoh K, Hosogaya S, Ozaki Y. Involvement of Hic-5 in platelet activation: integrin alphaIIbbeta3-dependent tyrosine phosphorylation and association with proline-rich tyrosine kinase 2. Biochem J 2001; 355:691 - 7; PMID: 11311131
   PubMed Web of Science ®Google Scholar
• Nishiya N, Tachibana K, Shibanuma M, Mashimo J-I. Kiyoshi Nose1. Hic-5-reduced cell spreading on fibronectin: competitive effects between paxillin and Hic-5 through interaction with focal adhesion kinase. Mol Cell Biol 2001; 21:5331 - 45; http://dx.doi.org/10.1128/MCB.21.16.5332-5345.2001
   Web of Science ®Google Scholar
• Shibanuma M, Iwabuchi Y, Nose K. Possible involvement of hic-5, a focal adhesion protein, in the differentiation of C2C12 myoblasts. Cell Struct Funct 2002; 27:21 - 7; http://dx.doi.org/10.1247/csf.27.21; PMID: 11937715
   PubMed Web of Science ®Google Scholar
• Gao ZL, Deblis R, Glenn H, Schwartz LM. Differential roles of HIC-5 isoforms in the regulation of cell death and myotube formation during myogenesis. Exp Cell Res 2007; 313:4000 - 14; http://dx.doi.org/10.1016/j.yexcr.2007.05.023; PMID: 17935713
   PubMed Web of Science ®Google Scholar
• Shibanuma M, Kim-Kaneyama JR, Sato S, Nose K. A LIM protein, Hic-5, functions as a potential coactivator for Sp1. J Cell Biochem 2004; 91:633 - 45; http://dx.doi.org/10.1002/jcb.10754; PMID: 14755691
   PubMed Web of Science ®Google Scholar
• Carneiro AM, Blakely RD. Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J Biol Chem 2006; 281:24769 - 80; http://dx.doi.org/10.1074/jbc.M603877200; PMID: 16803896
   PubMed Web of Science ®Google Scholar
• Hetey SE, Lalonde DP, Turner CE. Tyrosine-phosphorylated Hic-5 inhibits epidermal growth factor-induced lamellipodia formation. Exp Cell Res 2005; 311:147 - 56; http://dx.doi.org/10.1016/j.yexcr.2005.08.011; PMID: 16183059
   PubMed Web of Science ®Google Scholar
• Shibanuma M, Mashimo J, Kuroki T, Nose K. Characterization of the TGF beta 1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem 1994; 269:26767 - 74; PMID: 7929412
   PubMed Web of Science ®Google Scholar
• Heitzer MD, DeFranco DB. Hic-5/ARA55: a prostate stroma-specific AR coactivator. Steroids 2007; 72:218 - 20; http://dx.doi.org/10.1016/j.steroids.2006.11.010; PMID: 17166536
   PubMed Web of Science ®Google Scholar
• Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 2001; 58:289 - 94; http://dx.doi.org/10.1016/S0090-4295(01)01117-7; PMID: 11489729
   PubMed Web of Science ®Google Scholar
• Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci U S A 2003; 100:5124 - 9; http://dx.doi.org/10.1073/pnas.0530097100; PMID: 12700349
   PubMed Web of Science ®Google Scholar
• Mestayer1 C, Blanchère M, Jaubert F, Dufour B, Mowszowicz I. Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate 2003; 56:191 - 200
   Google Scholar
• Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004; 23:1377 - 91; http://dx.doi.org/10.1038/sj.onc.1207262; PMID: 14973550
   PubMed Web of Science ®Google Scholar
• Cui W, Wang X, Liu YC, Wan YL, Guo HJ, Zhu J. [Expression of HIC-5/ARA55 in colonrectal cancer and its mechanisms of action]. Beijing Da Xue Xue Bao 2006; 38:280 - 3; PMID: 16778972
   PubMedGoogle Scholar